Nasus Pharma Ltd. (NSRX) Stock Price & Analysis
Nasus Pharma Ltd. (NSRX) — MoonshotScore 46/100 (Fair band), calculated Nov 18, 2026. Price $2.55 (-5.56%), as of the Nov 19, 2026 trading session; market cap $29.9M.
Educational signal · not a buy or sell recommendation · How to read this
Nasus Pharma Ltd. · NSRX
Nasus Pharma Ltd. is a clinical-stage specialty pharmaceutical company focused on developing intranasal drugs for emergency medical conditions. Their lead products target severe allergies, anaphylaxis, and opioid overdose, utilizing a powder-based intranasal technology for rapid drug absorption.
Price as of Nov 19, 2026
Key Statistics
MoonshotScore v2 · Nasus Pharma (NSRX)
FairWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
Weak quality, stalling growth and an expensive valuation, though the balance sheet is only middling. Business Quality: Thin; Financial Safety: Okay; Valuation: Rich; Growth Durability: Shrinking; Momentum: Slipping.
- Altman Z 4.93 · Piotroski F 2
Holding back: weak fundamentals, soft growth
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 46 | Fair | |
| 47 | Fair | |
| 46 | Fair | |
| 46 | Fair | |
| 46 | Fair | |
| 46 | Fair |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $2.55 | |
| Change on the day | -5.56% | |
| Market capitalisation | $29.9M | — |
| Shares traded on the day | 4.7K |
Price & events
Other perspectives
Council score for Nasus Pharma (NSRX): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
6 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Sep 7, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: May 5, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On May 5, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Nasus Pharma (NSRX), and what does it report?
Short answer
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Nasus Pharma Ltd. (NSRX) is the company analyzed here. It employs 7 people. The market values it at $29.9M.
What are the financial strengths and risks for Nasus Pharma (NSRX)?
Short answer · as of
What is holding it back is weak fundamentals, soft growth. The distress and quality screens read Altman Z 4.93 · Piotroski F 2. Trailing ratios: ROA -87.8% · current ratio 8.77 · earnings yield -33.8% · free-cash-flow yield -13.4%.
What should you watch next at Nasus Pharma (NSRX)?
Short answer · as of
Analyst estimates on file carry FY2026 revenue $0.00 · EPS -1.13 · 0 analysts.
What the records here don't tell us
- The next earnings date is not yet scheduled in the calendar we read.
- No insider Form 4 transaction falls inside the window this page reads.
- No quarterly income statement is held for NSRX.
Checked against the records this page reads, on the dates shown above.
How does Nasus Pharma compare with its peers?
Short answer
Nasus Pharma's score ranks 7th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
| Company | Price | Market value | Score |
|---|---|---|---|
| $47.12 Nov 18, 2026 | $113B | 87 5-pillar Nov 18, 2026 | |
| $58.34 Nov 19, 2026 | $119B | 85 5-pillar Nov 18, 2026 | |
| $48.58 Nov 18, 2026 | $97.4B | 77 5-pillar Nov 18, 2026 | |
| $28.06 Nov 18, 2026 | $160B | 67 5-pillar Nov 18, 2026 | |
| $8.20 Nov 19, 2026 | $5.58B | 60 5-pillar Nov 18, 2026 | |
| $0.37 Nov 19, 2026 | $15.5M | 48 5-pillar Nov 18, 2026 | |
| Nasus Pharma (NSRX) — this page | $2.55 | $29.9M | 46 |
| $1.03 Nov 19, 2026 | $20.8M | 42 5-pillar Nov 18, 2026 | |
| $1.77 Nov 19, 2026 | $59.7M | 41 5-pillar Nov 18, 2026 | |
| $13.92 Nov 18, 2026 | $3.66B | 37 5-pillar Nov 18, 2026 | |
| $251.41 Nov 18, 2026 | $37.2B | 37 5-pillar Nov 18, 2026 | |
| $2.46 Nov 19, 2026 | $23.0M | 30 5-pillar Nov 18, 2026 | |
| $1.40 Nov 19, 2026 | $60.1M | 30 5-pillar Nov 18, 2026 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Revenue estimate
- $0.00
- EPS estimate
- $-1.13
Measured against a quoted price of $2.55 (as of Nov 19, 2026).
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held NSRX in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported NSRX in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about Nasus Pharma (NSRX)?
What Investors Ask About Nasus Pharma (NSRX)
These answers are editorial: 1 of these 9 answers is drawn from the NSRX research dossier (written Mar 16, 2026 by gemini-2.0-flash); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.
What does the MoonshotScore mean for NSRX?
NSRX carries the MoonshotScore stated above — the Fair band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers. Nasus Pharma Ltd. is a clinical-stage specialty pharmaceutical company focused on developing intranasal drugs for emergency medical conditions.
Is NSRX a good stock to buy?
Stock Expert AI does not rate NSRX buy, sell or hold. Nasus Pharma Ltd. carries a MoonshotScore, in the Fair band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the NSRX stock price today?
The last price recorded for Nasus Pharma Ltd. (NSRX), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
How does Nasus Pharma Ltd. navigate regulatory approval processes?
Nasus Pharma Ltd. navigates regulatory approval processes by adhering to strict guidelines set by regulatory agencies such as the FDA.
What are the key factors to evaluate for NSRX?
Nasus Pharma Ltd. (NSRX) holds a MoonshotScore in the low range. Analysts target $22.00 (+763%). Focus on intranasal drug delivery for emergency medical conditions positions the company in a niche market with the potential for rapid growth. Not financial advice.
How frequently does NSRX data refresh on this page?
NSRX's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven NSRX's recent stock price performance?
Nasus Pharma Ltd. (NSRX) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary intranasal drug delivery technology. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider NSRX overvalued or undervalued right now?
Nasus Pharma Ltd. (NSRX) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research NSRX before investing?
Before investing in Nasus Pharma Ltd. (NSRX), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 16, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 12 figures on this page — 5 from Financial Modeling Prep (FMP), 6 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com